SCHEMBL30303605

SCHEMBL30303605

C=CC(=O)Nc1cccc(-c2c(-c3ccc(Oc4cccc(C)n4)c(OC)c3)c3c(N)ncnc3n2C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 3/20 0.48
▸ FGFR1 P11362 2/20 0.48
▸ FGFR2 P21802 2/20 0.48
▸ FGFR3 P22607 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ SRC P12931 3/20 0.47
▸ BTK Q06187 5/20 0.43
▸ EGFR P00533 3/20 0.43
▸ ERBB2 P04626 1/20 0.43
▸ JAK3 P52333 5/20 0.41
▸ JAK2 O60674 3/20 0.41
▸ JAK1 P23458 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ GAK O14976 1/20 0.40
▸ EHMT2 Q96KQ7 1/20 0.40
▸ EHMT1 Q9H9B1 1/20 0.40
▸ PLCG1 P19174 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22675909 1.00 FGFR4 (0.48) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30303545 0.94 FGFR1 (0.55) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL22675910 0.94 FGFR1 (0.55) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL22675912 0.89 BTK (0.51) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30303995 0.89 BTK (0.51) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL22676155 0.87 FGFR1 (0.56) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30303255 0.87 FGFR1 (0.56) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL30303938 0.86 FGFR1 (0.51) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL22675920 0.86 FGFR1 (0.51) FGFR4FGFR1FGFR2FGFR3CYP3A4
SCHEMBL22676605 0.86 FGFR1 (0.52) FGFR4FGFR1FGFR2FGFR3CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522605-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-11780845-B2 FGFR inhibitors and methods of use thereof RELAY THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-06-22 — — US disclosed
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF D.E. SHAW RESEARCH, LLC 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192709-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR4 4/4885FGFR1 3/4885FGFR2 2/4885
US-20230104574-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF FGFR3, FGFR2, FGFR1 FGFR4 4/4885FGFR1 3/4885FGFR2 2/4885
US-11780845-B2 FGFR inhibitors and methods of use thereof FGFR3, FGFR2, FGFR1 FGFR4 4/4885FGFR1 3/4885FGFR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback